$REVB
REVELATION BIOSCIENCES, INC.

2021 Q3 Form 10-Q Financial Statement

#000121390021055498 Filed on October 29, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2020 Q3 2019 Q4
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $844.5K $870.00
YoY Change 96972.41%
% of Gross Profit
Research & Development $1.533M $450.0K
YoY Change 240.62%
% of Gross Profit
Depreciation & Amortization $6.071K $0.00
YoY Change
% of Gross Profit
Operating Expenses $844.5K $870.00
YoY Change 96972.41%
Operating Profit -$3.044M
YoY Change
Interest Expense $1.850K
YoY Change
% of Operating Profit
Other Income/Expense, Net $85.04K
YoY Change
Pretax Income -$757.6K -$870.00
YoY Change 86985.06%
Income Tax
% Of Pretax Income
Net Earnings -$757.6K -$870.00
YoY Change 86985.06%
Net Earnings / Revenue
Basic Earnings Per Share -$0.48
Diluted Earnings Per Share -$416.4K -$99.43
COMMON SHARES
Basic Shares Outstanding 6.292M
Diluted Shares Outstanding 6.292M

Balance Sheet

Concept 2021 Q3 2020 Q3 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $19.75K $3.321M
YoY Change -99.41%
Cash & Equivalents $3.321M
Short-Term Investments $19.75K
Other Short-Term Assets $19.33K $177.8K
YoY Change -89.13%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $39.08K $3.499M
YoY Change -98.88%
LONG-TERM ASSETS
Property, Plant & Equipment $167.2K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $73.52M
YoY Change
Total Long-Term Assets $73.52M $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $39.08K $3.499M
Total Long-Term Assets $73.52M $0.00
Total Assets $73.56M $3.499M
YoY Change 2002.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.031M
YoY Change
Accrued Expenses $1.183M $61.25K
YoY Change 1831.79%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $275.0K
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.738M $336.3K
YoY Change 1011.53%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.911M $3.150M
YoY Change -7.58%
Total Long-Term Liabilities $2.911M $3.150M
YoY Change -7.58%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.738M $336.3K
Total Long-Term Liabilities $2.911M $3.150M
Total Liabilities $6.649M $3.486M
YoY Change 90.71%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock $2.156K $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $66.91M $12.81K
YoY Change
Total Liabilities & Shareholders Equity $73.56M $3.499M
YoY Change 2002.15%

Cashflow Statement

Concept 2021 Q3 2020 Q3 2019 Q4
OPERATING ACTIVITIES
Net Income -$757.6K -$870.00
YoY Change 86985.06%
Depreciation, Depletion And Amortization $6.071K $0.00
YoY Change
Cash From Operating Activities -$282.0K -$8.550K
YoY Change 3197.89%
INVESTING ACTIVITIES
Capital Expenditures -$148.1K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $282.0K
YoY Change
Cash From Investing Activities $282.0K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 3.330M
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -282.0K -8.550K
Cash From Investing Activities 282.0K 0.000
Cash From Financing Activities 0.000 3.330M
Net Change In Cash -10.00 3.321M
YoY Change -100.0%
FREE CASH FLOW
Cash From Operating Activities -$282.0K -$8.550K
Capital Expenditures -$148.1K $0.00
Free Cash Flow -$133.8K -$8.550K
YoY Change 1465.5%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2020Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
25000 USD
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
USD
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
USD
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
USD
CY2020Q3 us-gaap Interest Income Other
InterestIncomeOther
USD
CY2021Q3 us-gaap Held To Maturity Securities Transferred To Trading Securities Unrealized Gain Loss
HeldToMaturitySecuritiesTransferredToTradingSecuritiesUnrealizedGainLoss
USD
CY2020Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
USD
CY2020Q3 paic Cancellation Of Founders Shares
CancellationOfFoundersShares
USD
paic Interest Earned On Cash Held In Trust Account
InterestEarnedOnCashHeldInTrustAccount
USD
paic Unrealized Loss On Marketable Securities
UnrealizedLossOnMarketableSecurities
USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
USD
us-gaap Increase Decrease In Prepaid Insurance
IncreaseDecreaseInPrepaidInsurance
USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
USD
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
USD
us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
USD
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
USD
paic Increase Decrease In Deferred Offering Costs
IncreaseDecreaseInDeferredOfferingCosts
USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
USD
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
USD
paic Deferred Offering Costs In Accrued Liabilities
DeferredOfferingCostsInAccruedLiabilities
USD
paic Common Stock Issued In Partial Relief Of Related Party Note Payable
CommonStockIssuedInPartialReliefOfRelatedPartyNotePayable
USD
paic Cancellation Of Founders In Shares
CancellationOfFoundersInShares
USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
USD

Files In Submission

Name View Source Status
0001213900-21-055498-index-headers.html Edgar Link pending
0001213900-21-055498-index.html Edgar Link pending
0001213900-21-055498.txt Edgar Link pending
0001213900-21-055498-xbrl.zip Edgar Link pending
f10q0921ex31-1_petraacqu.htm Edgar Link pending
f10q0921ex31-2_petraacqu.htm Edgar Link pending
f10q0921ex32-1_petraacqu.htm Edgar Link pending
f10q0921ex32-2_petraacqu.htm Edgar Link pending
f10q0921_petraacq.htm Edgar Link pending
f10q0921_petraacq_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
paic-20210930.xsd Edgar Link pending
paic-20210930_cal.xml Edgar Link unprocessable
paic-20210930_def.xml Edgar Link unprocessable
paic-20210930_lab.xml Edgar Link unprocessable
paic-20210930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending